Zobrazeno 1 - 10
of 38
pro vyhledávání: '"J M, López Gómez"'
Publikováno v:
Internal medicine journal. 45(5)
Crescentic glomerulonephritis (CGN) is a histological finding that implies rapid deterioration of renal function and can be related to different diseases, such as type 1 or anti-glomerular basement membrane antibody (Goodpasture) disease, type 2 or i
Autor:
J M, López-Gómez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 31(6)
Autor:
J M, López Gómez, B, Sacristán Enciso, M, Micó, F, Arias Meneses, F, de Sande Medel, S, Alejo
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 31(5)
The aim of this study was to assess serum cystatin C and urinary albumin in the early detection of impairment in cardiovascular and renal function. MATERIAL ANS METHODS: Cystatin C was quantified in sera from healthy people, moreover, cystatin C was
Autor:
J, Portolés, J, Ocaña, P, López-Sánchez, M, Gómez, M T, Rivera, G, Del Peso, E, Corchete, M A, Bajo, J R, Rodríguez-Palomares, A, Fernández-Perpen, J M, López-Gómez, J, Martín-Gago
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 30(5)
In 2007 the Scientific Quality-technical and Improvement of Quality in Peritoneal Dialysis was edited. It includes several quality indicators. As far as we know, only some groups of work had evaluated these indicators, with inconclusive results.To st
Autor:
J M, López-Gómez, A L Martín, de Francisco, J, Montenegro, C, de Santiago, M, Vera, C, Donapetry, M, Villaverde
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 30(1)
Darbepoetin alpha (DA) administered every-other-week (Q2W) is efficacious and safe for the treatment of anaemia in patients undergoing dialysis. There are no data available regarding the evolution of erythropoietic resistance index (ERI) after conver
Autor:
J M, López Gómez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 28
1. All patients with anemia secondary to CKD should be treated and evaluated for possible treatment, irrespective of underlying disease, associated comorbidity or possibility of kidney replacement therapy. 2. In patients treated with ESAs, Hb concent
Autor:
J M, López Gómez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 28
SUMMARY In most current hemodialysis (HD) units, two of the most significant problems are vascular access and the steady increase in incident elderly patients. Both are risk factors for morbidity and mortality that require frequent hospitalizations a
Autor:
J, Kanter, M Carretero, Puerta, R Pérez, García, J M López, Gómez, R, Jofré, P Benítez, Rodríguez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 28(4)
on line haemodiafiltration provides the greatest clearance for low and high-molecular weight uremic toxins, which is associated with a lower risk of mortality in our patients. Nowadays, there's increasing evidence about the need of achieving at least
Autor:
A, Vega, R, Pérez García, S, Abad, E, Verde, J M, López Gómez, R, Jofré, M, Puerta, P, Rodríguez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 28(3)
Peripheral vascular disease (PVD) is a common disease among patients undergoing hemodialysis leading to increase morbidity and mortality with a high risk of inflammation and sepsis. The aim of the present study was to determinate PVD prevalence in ou
Autor:
E, Coll, R, Pérez-García, P, Rodríguez-Benítez, M, Ortega, P, Martínez Miguel, R, Jofré, J M, López-Gómez
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 27(6)
the purpose of this study was to evaluate blood acetate levels and its correlation with clinical and analytical changes in hemodialysis patients treated with standard bicarbonate dialysate compared to treatment with acetate-free bicarbonate dialysate